Sanofi Consumer Healthcare India Posts Profitable Growth, Achieving 7% Revenue Rise in Q2 FY26
Mumbai, July 28, 2026: Sanofi Consumer Healthcare India Limited released its financial results for the second quarter (Q2) and half-year (HY) ending June 30, 2026, demonstrating profitable growth across the Consumer Healthcare sector. The company reported Revenue from Operations of ₹2,357 million for Q2 ‘26, with Profit Before Tax (PBT) reaching ₹919 million, marking a 16% year-on-year increase in PBT for the quarter.The performance highlights reflect targeted investments and disciplined execution across business segments. Domestic sales grew by 12%, attributed to product relaunches, while export sales saw a decline of 9%, following a high base.
For the first half of the financial year (HY), Sanofi Consumer Healthcare India Limited reported Revenue from Operations at ₹4,649 million, achieving an overall growth rate of 18%. Profit Before Tax for the six months stood at ₹1,826 million, reflecting a 25% increase. Domestic sales increased by 14%, aided by successful product relaunches, while export sales grew by 27%.
Himanshu Bakshi, Managing Director of Sanofi Consumer Healthcare India Limited, stated that the Q2 ‘26 results reflect disciplined execution across all fronts. He reinforced confidence in the company's strategy, noting that targeted investments behind brands and go-to-market capabilities are successfully translating into profitable growth and market share gains within most brands.
The company continues to operate as a single business segment within the Pharmaceutical sector. Furthermore, the company noted that comparability of results across certain periods is impacted due to previous voluntary product recalls and subsequent relaunches, which occurred in 2024 and 2025.
Key financial metrics for the quarter and half year ended June 30, 2026, are detailed below:
| Metric | Quarter Ended 30.06.2026 (Unaudited) | Half Year Ended 30.06.2026 (Unaudited) |
|---|---|---|
| Revenue from Operations | ₹2,357 million | ₹4,649 million |
| Other Income | ₹63 million | ₹119 million |
| Total Income | ₹2,420 million | ₹4,768 million |
| Profit Before Tax (PBT) | ₹919 million | ₹1,826 million |
For reference, a comparison of the key financial figures across the relevant periods is provided in the table below:
| Particulars | Qtr. ended 30.06.2026 (Unaudited) | Qtr. ended 31.03.2026 (Unaudited) | Qtr. ended 30.06.2025 (Unaudited) | HY Ended 30.06.2026 (Unaudited) | HY Ended 30.06.2025 (Unaudited) | Year ended 31.12.2025 (Audited) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 2,357 | 2,292 | 2,209 | 4,649 | 3,935 | 8,784 |
| Total Income (1+2) | 2,420 | 2,348 | 2,265 | 4,768 | 4,043 | 8,968 |
| Profit before exceptional item and tax | 919 | 907 | 723 | 1,826 | 1,391 | 3,137 |
SANOFICONR Stock Price Movement
Today, shares of Sanofi Consumer Healthcare India Limited edged higher in a post-market session, settling at ₹4,707.20 after gaining 0.34%. The stock saw robust trading activity, with 84,199 shares being traded during the day, closing well above its lower bound of ₹4,652.10.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.